Profile of REDHILL BIOPHARMA LTD-SP ADR(NASDAQ:RDHL) stock

REDHILL BIOPHARMA LTD-SP ADR0.2294

NASDAQ:RDHL (2/3/2023, 7:04:38 PM)+0 (+1.5%)

After market: 0.2231 -0.01 (-2.75%)

Chartmill TA Rating

Chartmill Setup Rating

Sector

GICS Sector	Health Care
GICS Industry	Pharmaceuticals

Chartmill FA Rating

Valuation		Growth
Profitability		Health
Dividend

Overview

Earnings (Last)	11-07 2022-11-07/bmo	Earnings (Next)	03-15 2023-03-15/amc
Ins Owners	N/A	Inst Owners	3.12%
Market Cap	20.92M	Shares	91.20M
PE	N/A	Fwd PE	N/A
Dividend Yield	N/A	Analysts	82.86
IPO	02-01 2011-02-01

Stock Screener Links

GICS Sector Stock Screener

Find competitors from the same sector on the USA

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

Company Profile

RedHill Biopharma Ltd. develops medicines for gastrointestinal and infectious diseases. The firm is focused on the commercialization in the United States (U.S.) of the GI-related products, Movantik (naloxegol),Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). A part form Company's pipeline consists of six therapeutic candidates RHB-204 dedicated to Nontuberculous mycobacterial (NTM) treatment, RHB-104 dedicated to Crohn's disease, RHB-102 antiemetic drug ondansetron, in development for multiple gastrointestinal indications, RHB-106 an oral capsule formulation for bowel preparation, Opaganib an inhibitor, administered orally, with anticancer, anti-inflammatory and anti-viral activities and RHB-107 inhibitor of serine proteases targeting multiple indications, including COVID-19, cancer, inflammatory lung diseases and gastrointestinal diseases.